The GTF2I Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the GTF2I gene has been functionally disrupted. This heterogeneous pool of HeLa cells carries diverse loss-of-function mutations across the GTF2I locus, providing a robust model for studying gene function without the limitations of monoclonal artifacts. The use of polyclonal knockout cells ensures broad genetic diversity while maintaining potent target-gene ablation. This product serves as a versatile tool for investigating the roles of GTF2I in transcriptional regulation and signal transduction within an epithelial cancer context.
The host cell line, HeLa, is a well-established human cervical adenocarcinoma epithelial cell line derived from a patient with cervical carcinoma. HeLa cells are HPV18-positive and exhibit adherent epithelial morphology. They are one of the most widely used models in cancer biology, signaling research, and drug discovery due to their robust growth, ease of manipulation, and extensive characterization. Their epithelial origin and HPV-driven transformation make them particularly suitable for studying the interplay between viral oncogenesis and host transcription factors such as GTF2I.
GTF2I (General Transcription Factor II-I) is a multifunctional transcription factor that regulates initiator element (Inr)-dependent transcription, linking extracellular signals to gene expression. It is activated by phosphorylation through kinases such as BTK, Syk, and MAP kinases, leading to transcriptional modulation of target genes including c-FOS and immunoglobulin heavy chain loci. GTF2I integrates inputs from B cell receptor signaling, NF-??B signaling, calcium/NFAT pathways, and the MAPK cascade. It interacts with cofactors USF1, SRF, NFAT, p300/CBP, and HDACs to orchestrate context-dependent transcriptional programs. In HeLa cells, GTF2I influences both basal and signal-induced gene expression, making its disruption a valuable model for studying epithelial signaling networks.
Knockout of GTF2I in HeLa cells disrupts the transcriptional programs downstream of growth factor receptors and BCR-like signaling components that are active in epithelial cancers. Because GTF2I functions at the nexus of pathways regulating proliferation, survival, and immune-related gene expression, its loss creates a cellular model to examine how these processes are rewired in cervical carcinoma. This model is particularly relevant for studying the molecular mechanisms of Williams-Beuren syndrome, thymomas, and autoimmune diseases, where GTF2I dysregulation has been implicated. The epithelial context of HeLa cells further provides a platform to investigate tissue-specific functions of GTF2I that may differ from its roles in lymphoid cells.
Applications include dissecting transcriptional regulation mechanisms, analyzing cancer cell signaling, profiling immune-related gene expression, performing drug sensitivity screening, and measuring apoptosis and proliferation. Representative techniques such as western blotting, RT-qPCR, RNA-seq, immunofluorescence, dual-luciferase reporter assays, co-immunoprecipitation, and cell viability assays are well-suited for this knockout model. These assays provide comprehensive tools to investigate GTF2I function in epithelial cells. For further inquiries, please contact Ascent Research.
